Abstract
This retrospective study aims at confirming the efficacy and safety of low dose rituximab and pulse cyclophosphamide in the treatment of refractory AIHA in adults and making comparison of the two. Forty-nine adult patients with refractory AIHA have been enrolled. Results showed low dose rituximab combined with steroid therapy (group B) got more CR (78.9 %, 15/19) compared to that in intermittent intravenous cyclophosphamide combined with steroid therapy (group A) (42.1 %, 8/19) (P = 0.04) at 6 months after treatment. The hemoglobin level in group B was higher than group A at the time point of 1 month (P = 0.02) after treatments. The RFS in group A was 87.9 % at 6 months and 82.7 % at 12 months, which were no significant difference with group B (91.1 % at 6 months and 86.0 % at 12 months) (P = 0.81). Both the two therapies were well tolerated with pulmonary infections as the most common side effects. In conclusion, low dose rituximab combined with steroid therapy presents to be a better choice in the treatment of refractory AIHA in adults comparing with pulse cyclophosphamide therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia[J]. Am J Hematol. 2002;69(4):258–71.
Michel M. Classification and therapeutic approaches in autoimmune hemolytic anemia: an update. Expert Rev Hematol. 2011;4:607–18.
Packman CH. Hemolytic anemia due to warm autoandibodies. Blood Rev. 2008;22:17–31.
King KE, Ness PM. Treatment of autoimmune hemolytic anemia. Semin Hematol. 2005;42:131–6.
Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias[J]. Haematologica. 2014;99(10):1547–54.
Garvey B. Rituximab in the treatment of autoimmune haematological disorders[J]. Br J Haematol. 2008;141(2):149–69.
Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20[J]. Blood. 1994;83(2):435–45.
McCune WJ, Golbus J, Zeldes W, et al. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus[J]. N Engl J Med. 1988;318(22):1423–31.
Zupańska B, Sylwestrowicz T, Pawelski S. The results of prolonged treatment of autoimmune haemolytic anaemia[J]. Haematologia. 1981;14(4):425–33.
Sakalová A, Hrubisko M. Cyclophosphamide in the treatment of immune hemocytopenias[J]. Folia haematologica (Leipzig, Germany: 1928). 1975;102(5):559.
Verlin M, Laros RK, Penner JA. Treatment of refractory thrombocytopenic purpura with cyclophosphamide[J]. Am J Hematol. 1976;1(1):97–104.
Jones RJ, Barber JP, Vala MS, et al. Assessment of aldehyde dehydrogenase in viable cells[J]. Blood. 1995;85(10):2742–6.
Hayag MV, Cohen JA, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris[J]. J Am Acad Dermatol. 2000;43(6):1065–9.
Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia[J]. Eur J Haematol. 2013;91(6):546–51.
Akpek G, McAneny D, Weintraub L. Comparative response to splenectomy in coombs-positive autoimmune hemolytic anemia with or without associated disease[J]. Am J Hematol. 1999;61(2):98–102.
Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: new insights based on a single-center experience with 60 patients[J]. Am J Hematol. 2014;89(9):E150–5.
Thabet AF, Faisal M. Pulse cyclophosphamide therapy in refractory warm autoimmune hemolytic anemia: a new perspective[J]. Indian J Hematol Blood Transfus. 2014;30(4):313–8.
Lechner K, Jäger U. How I treat autoimmune hemolytic anemias in adults[J]. Blood. 2010;116(11):1831–8.
Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia[J]. Br J Haematol. 2013;163(3):393–9.
Zhang ZN. Hematology. Beijing: People’s Medical Publishing House; 2013.
Maung SW, Leahy M, O’Leary HM, et al. A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia[J]. Br J Haematol. 2013;163(1):118–22.
D’Arena G, Califano C, Annunziata M, et al. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients[J]. Eur J Haematol. 2007;79(1):53–8.
Acknowledgments
This work was supported by the National Natural Science Foundation of China (Grant Nos. 81570106, 81570111, 814000888, 81400085), the Tianjin Municipal Natural Science Foundation (Grant Nos. 14JCYBJC25400, 15JCYBJC24300).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
All authors declare that they have no conflict of interest.
Additional information
R. Fu and S. Yan contributed equally to this manuscript
About this article
Cite this article
Fu, R., Yan, S., Wang, X. et al. A monocentric retrospective study comparing pulse cyclophosphamide therapy versus low dose rituximab in the treatment of refractory autoimmune hemolytic anemia in adults. Int J Hematol 104, 462–467 (2016). https://doi.org/10.1007/s12185-016-2056-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-016-2056-5